Displaying 1 - 8 of 8
| Active Ingredient | CODEINE PHOSPHATE |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | Mild to moderate pain in patients intolerant of aspirin. |
| Caution | Syncope, nausea, constipation, sedation, dependence. May cause drowsiness. Warn patients re driving: Avoid alcohol and other depressants. Avoid in children under 1 year old. |
| Dose Range | Adult: 30 60mg every 4 6 hours. Maximum 240mg daily. Reduce dose by 75% in moderate and 50% in severe renal failure. Take with food or milk. Paediatric under 12 years: 0.5-1mg/kgevery 4-6 hours. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FENTANYL CITRATE |
| Therapeutic Class | OPIATE AGONISTS |
| Indications |
Adjunct to general anaesthetics, anaesthetic for induction and maintenance. |
| Caution | Respiratory depression and apnea. Transient hypotension may follow intravenous dosage. An opiate antagonist and facilities for administration of oxygen and controlled respiration should be available More ... |
| Dose Range |
As an adjunct to general anesthesia, fentany l may be given in low-dose, moderate-dose, or high-dose regimens. Low dose: 2mcg/kg; moderate dose: initial IV dose of 2-20 mcg/kg is administered; additional doses of 25-100 mcg may be given IV or IM as nece |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MORPHINE |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | Severe visceral pain, post operative pain, terminal malignancies or bone pain, my ocardial infarction. |
| Caution | Drowsiness,nausea, vomiting, constipation,depression of respiration and cough. Urinary retention, tolerance and dependence. Advisable to use concurrent antiemetics and prophylaxis of constipation. |
| Dose Range |
Immediate release: 5-20mg every 4 hours. Loading dose may be required. Modified release given as once or twice daily dosing. See BDS supply protocols pg. 5. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MORPHINE SULPHATE |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | Severe visceral pain, post operative pain, terminal malignancies or bone pain, my ocardial infarction. |
| Caution | Drowsiness,nausea, vomiting, constipation,depression of respiration and cough. Urinary retention, tolerance and dependence. Advisable to use concurrent antiemetics and prophylaxis of constipation. |
| Dose Range |
Immediate release: 5-20mg every 4 hours. Loading dose may be required. Modified release given as once or twice daily dosing. See BDS supply protocols pg. 5. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MORPHINE SULPHATE SR |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PETHIDINE |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | Obstetric analgesia. |
| Caution | See morphine (but less constipating). |
| Dose Range | 50 to 100 mg may be given by intramuscular or subcutaneous injection as soon as contractions occur at regular intervals. This dose may be repeated after 1 to 3 hours if necessary up to a maximum of 400 mg in 24 hours. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SUFENTANYL |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | Analgesic adjunct in anaesthesia and as a primary anaesthetic in procedures requiring assisted ventilation. Obstetric analgesia. |
| Caution | As for fentany l. |
| Dose Range |
Adjunct: Total IV dose should not exceed 1mcg/kg/hoir for procedures lasting up to 8 hours.Primary anaesthesia: 8-30mcg/kg with 100% oxygen.Obstetric analgesia: 10-15mck with 10ml bupivacaine 0.125% (or its equivalent), repeated twice at not less than 1 |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | TRAMADOL |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | Moderate to severe pain. |
| Caution | Drowsiness, dizziness, headache, fatigue, restlessness, nausea, vomiting, constipation, dry mouth, diaphoresis. |
| Dose Range |
Adult and children 12 years and over: 50-100 mg every 4-6 hours or modified-release preparation once or twice daily, to a max.of 400mg daily. Reduce dose in patients with renal or hepatic dysfunction. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |